Clinical effectiveness and safety of vildagliptin in >19 000 patients with type 2 diabetes: the GUARD study
The present GUARD study was a prospective, non‐interventional study evaluating the clinical effectiveness, safety and tolerability of vildagliptin with or without metformin in adult patients with type 2 diabetes mellitus (T2DM) studied in routine clinical practice. Patients were enrolled from countr...
Saved in:
Published in | Diabetes, obesity & metabolism Vol. 17; no. 6; pp. 603 - 607 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford, UK
Blackwell Publishing Ltd
01.06.2015
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present GUARD study was a prospective, non‐interventional study evaluating the clinical effectiveness, safety and tolerability of vildagliptin with or without metformin in adult patients with type 2 diabetes mellitus (T2DM) studied in routine clinical practice. Patients were enrolled from countries across four geographical regions. The primary endpoint was change in glycated haemoglobin (HbA1c) concentration from baseline after 24 weeks of treatment with vildagliptin with or without metformin. Of 19 331 patients analysed, 3511 received vildagliptin and 15 820 received vildagliptin plus metformin. At week 24, the mean HbA1c was reduced significantly from baseline by −1.27% (vildagliptin: −1.17%; vildagliptin plus metformin: −1.29%; p < 0.0001). Significant reductions in HbA1c from baseline were consistently reported regardless of patient age, body mass index (BMI) or baseline HbA1c. Weight and BMI were also significantly reduced from baseline. Vildagliptin treatment with or without metformin was generally well tolerated. It provided clinically relevant glycaemic and weight control, and was well tolerated in a large multi‐ethnic population of patients with T2DM studied in routine clinical practice. |
---|---|
Bibliography: | Figure S1. Proportion of patients achieving glycated haemoglobin (HbA1c) target ≤7.0% at week 24.Table S1. Patient disposition.Table S2. Numbers of patients from participating countries/regions.Table S3. Patient demographics and baseline characteristics.Table S4. Baseline glycated haemoglobin values by patient subpopulation.Table S5. Adverse events and serious adverse events.Table S6. Numbers of patients achieving glycated haemoglobin (HbA1c) target of ≤7.0% at study end, stratified by baseline HbA1c.Appendix S1. Supplementary methods.Appendix S2. Supplementary results. ArticleID:DOM12436 Novartis Pharma AG, Basel, Switzerland istex:9C74F0DD7ECF54B25B722FCE08AE0F1EFAF4342F ark:/67375/WNG-2TB303T1-R ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Undefined-2 |
ISSN: | 1462-8902 1463-1326 |
DOI: | 10.1111/dom.12436 |